New: the Income Securities Screening Form now screens by price, yield, S&P rating, call status and trading volume, and you can save your searches to run again. Try the updated form.
Autolus Therapeutics plc (AUTL)
AUTL · NGS · ADR · CUSIP 05280R100
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for AUTL and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
05280R100
IPO
6/22/2018 · 8.82 Million ADRs @ $17.00/ADR
Prospectus
IPO prospectus »
ADR Ratio
1:1
Business: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells.

Company Contact

CEO
Christian Itin
PFO
Dominic Moreland
Investor Relations
Susan A Noonan, S.A. Noonan Communications, LLC · 212-966-3650 · susan@sanoonan.com
General Email
IR@autolus.com
SEC EDGAR Filings
View filings »